Palliative Care for Metastatic Symptomatic CRPC

  • Kyo Chul KooEmail author


Symptom development in advanced castration-resistant prostate cancer (CRPC) patients can be attributed to local invasion of the tumor, metastasis to the bone, or compression of the spinal cord. Along the course of disease progression, 50–70% of the patients will eventually develop complications. Bone metastasis and consequent skeletal complications are the most common manifestations which may increase the risk of death from prostate cancer and decrease life quality. The clinical manifestations of bone metastasis include pain, skeletal-related events, and additional medical cost. Advancements in the understanding of the disease have resulted in the development of new palliation strategies. In this chapter, we examine several interventional options for local and systemic disease manifestation, bone-targeted palliative agents, and bone-targeted agents which potentially improve survival and management strategies for spinal cord compression. These treatments include various agents, namely, bisphosphonates, human monoclonal antibodies, and alpha- and beta-emitting radiopharmaceuticals.


Palliative care Prostatic neoplasms Castration-resistant Neoplasm metastasis 


  1. 1.
    Cameron MG, Kersten C, Guren MG, Fosså SD, Vistad I. Palliative pelvic radiotherapy of symptomatic incurable prostate cancer—a systematic review. Radiother Oncol. 2014;110(1):55–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain. 1991;45(1):45–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9(3):509–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Wagner G. Frequency of pain in patients with cancer. Recent Results Cancer Res. 1984;89:64–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Tiedje LB, Kingry MJ, Stommel M. Patient attitudes concerning health behaviors during pregnancy: initial development of a questionnaire. Health Educ Q. 1992;19(4):481–93.CrossRefPubMedGoogle Scholar
  8. 8.
    Pathological fractures due to bone metastases. Br Med J (Clin Res Ed). 1981;283(6294):748.Google Scholar
  9. 9.
    Galasko CS. The management of skeletal metastases. J R Coll Surg Edinb. 1980;25(3):144–61.PubMedGoogle Scholar
  10. 10.
    Lane MD, Le HB, Lee S, Young C, Heran MK, Badii M, et al. Combination radiofrequency ablation and cementoplasty for palliative treatment of painful neoplastic bone metastasis: experience with 53 treated lesions in 36 patients. Skelet Radiol. 2011;40(1):25–32.CrossRefGoogle Scholar
  11. 11.
    Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006;18(4):CD003448.Google Scholar
  12. 12.
    Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005;31(Suppl 3):19–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol. 2006;13(4):3180–8.PubMedGoogle Scholar
  17. 17.
    Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist. 2009;14(2):181–91.CrossRefPubMedGoogle Scholar
  18. 18.
    Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Roqué I, Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011;(7):CD003347.
  21. 21.
    Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–9.PubMedGoogle Scholar
  23. 23.
    Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Grossman SA, Lossignol D. Diagnosis and treatment of epidural metastases. Oncology (Williston Park). 1990;4(4):47–54; discussion 55,58.Google Scholar
  25. 25.
    George R, Jeba J, Ramkumar G, Chacko AG, Leng M, Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev. 2015;9:CD006716.Google Scholar
  26. 26.
    Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologyYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations